IDEAYA Biosciences Announces Strategic Updates and 2025 Corporate Guidance
Key Insights
IDEAYA Biosciences has a strong financial position with $1.2 billion in cash, expected to fund operations into at least 2028.
A Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is planned for initiation in the first half of 2025.
Clinical program updates for IDE397 in combination with Trodelvy® in MTAP-deletion urothelial cancer (search) are expected in 2025.
IDEAYA Biosciences (IDYA) has announced strategic updates and its 2025 corporate guidance, highlighting progress in clinical trials and expansion of its precision medicine oncology programs. The announcement was made during the 43rd Annual J.P. Morgan Healthcare Conference. IDEAYA's robust financial position and advancements in clinical trials signal a promising outlook for the company's future endeavors in targeted cancer therapies.
Financial Stability and Pipeline Advancement
IDEAYA reported a strong financial standing with $1.2 billion in cash, cash equivalents, and marketable securities as of September 30, 2024. This is projected to fund operations into at least 2028. This financial stability enables IDEAYA to advance its diverse pipeline of precision medicine oncology programs.
Darovasertib Program Updates
Significant progress has been made with darovasertib, a potential first-in-class Phase 2/3 PKC inhibitor. The focus is on treating Metastatic Uveal Melanoma (search) (MUM) and Uveal Melanoma (UM). Enrollment in the darovasertib and crizotinib combination trial for first-line (1L) patients with HLA-A2-negative MUM has exceeded 200 patients as of January 6, 2025. The median progression-free survival readout for this trial is targeted by year-end 2025, contingent on enrollment status and data maturity.
IDEAYA also anticipates a Phase 2 1L MUM median overall survival readout for the darovasertib and crizotinib combination in approximately 38 1L MUM patients in 2025. Furthermore, a Phase 2 neoadjuvant UM clinical data update for darovasertib in over 75 patients and a regulatory update are expected in 2025. The initiation of a Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is planned for the first half of 2025.
IDE397 Program for MTAP-deletion Solid Tumors
IDEAYA is also advancing IDE397, a potential first-in-class Phase 2 MAT2A Inhibitor, targeting MTAP-deletion solid tumors. Clinical program updates for the Phase 1/2 study of IDE397 in combination with Trodelvy® in MTAP-deletion urothelial cancer (search) (UC) are expected in 2025. The company aims to enable a wholly-owned IDE397 + IDE892 (IDEAYA PRMT5) clinical combination in the second half of 2025, targeting MTAP-deletion non-small cell lung cancer (search) (NSCLC).
Expansion of Clinical Programs and IND Filings
IDEAYA is targeting three IND filings in 2025, representing the company's 7th, 8th, and 9th potential clinical-stage precision medicine oncology programs. These include IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, IDE034, a potential first-in-class B7H3/PTK7 TOP1i bispecific ADC, and IDE251, a potential first-in-class KAT6/7 dual inhibitor development candidate.
IDE849 (SHR-4849) Clinical Updates
Clinical program updates for IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 (search) TOP1i ADC targeting Small Cell Lung Cancer (search) (SCLC) and Neuroendocrine Tumors (search) (NETs), are also targeted in 2025. Updated clinical program slides, including preclinical product profiles and SCLC patient case studies, have been provided in the JPM 2025 corporate presentation.
Other Pipeline Developments
IDEAYA is also progressing other programs, including IDE275 (GSK959), a potential first-in-class Phase 1 Werner Helicase (search) program targeting MSI-high solid tumors (search), and IDE161, a potential first-in-class Phase 1 PARG (search) inhibitor program targeting solid tumors. Clinical combinations of IDE161 with Topo-ADCs are being targeted in 2025.
IDE705 (GSK101), a potential first-in-class Phase 1 Pol Theta Helicase (search) Inhibitor targeting homologous recombination deficiency (HRD) solid tumors, is targeting Phase 2 expansion in HRD solid tumors (search), potentially enabling a $10 million milestone payment from GSK.